Azathioprine-Associated Anemia
Azathioprine can cause anemia by causing bone marrow suppression (myelosuppression), which may present as anemia, macrocytosis, and/or pancytopenia. [1][2]
Mechanism of Anemia
Azathioprine toxicity can decrease blood cell production in the bone marrow, which can reduce hemoglobin. [1][2]
Clinical Spectrum of Hematologic Effects
Severe anemia may occur as part of broader cytopenias including leukopenia and thrombocytopenia. [1][3]
Incidence and Risk Context
Hematologic adverse effects including anemias (including macrocytic anemia) and/or pancytopenia are recognized risks in patients treated with azathioprine. [1][3]
Monitoring and When to Seek Urgent Assessment
Complete blood counts (including platelet counts) are recommended for monitoring during azathioprine therapy, because bone marrow depression can occur. [1][4]
Dose- and Therapy-Related Considerations
Bone marrow depression can require dose reduction or temporary withdrawal when there is a rapid fall in blood counts or persistent cytopenias. [1]
Suggested Evaluation of New or Worsening Anemia on Azathioprine
New anemia during azathioprine treatment should prompt evaluation for azathioprine-induced cytopenia with repeat CBC and medication review, including assessment for concomitant causes of anemia. [1][2]